Showing results (491-500 of 1,188) with videos related to
Sort By:
Pageof 119
Pharmaceutical Statistics|February 18, 2026
New, Shorter Small-Sample Intervals for Vaccine EfficacyMauro Gasparini, Vincenzo Di Trani, Marco RattaPharmaceutical Statistics|February 26, 2026
Assessment of Responder Analyses for Patient-Reported Outcomes With Varying Variability Between Intervention Groups: Maximum Responder Threshold and EffectJoseph C Cappelleri, Jia Ma, Manuela Di Fusco, et al.Pharmaceutical Statistics|March 17, 2026
Paired and AB/BA Cross-Over Design in Early Phase Clinical Trials: A Closer Look at Within-Subject Variance BiasMartin J Wolfsegger, Peixin Xu, Amy Cotterill, et al.Pharmaceutical Statistics|March 15, 2026
Penalized Variable Selection for Joint AFT Random-Effect Model With Clustered Competing-Risks DataLin Hao, Il Do HaPharmaceutical Statistics|May 20, 2021
The detailed clinical objectives approach to designing clinical trials and choosing estimandsJames Bell, Alan Hamilton, Oliver Sailer, et al.Pharmaceutical Statistics|December 3, 2016
Disentangling estimands and the intention-to-treat principleAnn-Kristin Leuchs, Andreas Brandt, Jörg Zinserling, et al.Pharmaceutical Statistics|April 3, 2014
A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trialsJ Bowden, A ManderPharmaceutical Statistics|April 29, 2008
Assessing the impact of ICH E9David Brown, Simon Day, Rob Hemmings, et al.Pharmaceutical Statistics|May 10, 2014
Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Andrew Stone, Nicola SchmittPharmaceutical Statistics|April 5, 2008
Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterionJürgen Hummel, Sue McKendrick, Charlie Brindley, et al.Pageof 119